The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Subscribe To Our Newsletter & Stay Updated
